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Diabetic retinopathy (DR), a blood–retinal barrier 
disorder, is the main complication of diabetes and the leading 
cause of blindness in working-age adults [1]. The major 
pathological features at advanced stages of the disease are 
the abnormal neovascularization due to hypoxia and blood 
leakage as a result of inner blood–retinal barrier breakdown 
[1,2]. The blood–retinal barrier (BRB) is responsible for 
the homeostasis of the neuroretina and is composed of two 
structures: the inner BRB (iBRB), formed by tight junctions 
between the endothelial cells of the retinal vessels, and the 
outer BRB (oBRB), formed by intercellular tight junctions in 
the RPE monolayer [3-5].
Most of the studies on the pathophysiology of DR focused 
on the iBRB breakdown and neuroretina damage [6-9], with 
little attention to the effects of diabetes on the oBRB and RPE 
cells. As the RPE is responsible, among others, for the trans-
port of nutrients, such as glucose, ions, and water, and the 
secretion of factors crucial for the homeostasis of the neuro-
retina such as the pigment epithelium-derived factor (PEDF) 
and vascular endothelial growth factor (VEGF) [2,10], the 
role of the RPE in DR is worth investigating. The healthy 
eye is characterized by low levels of angiogenic VEGF and 
high levels of antiangiogenic factors, such as PEDF [5]. This 
balance is disrupted by ischemia during the pathogenesis 
of DR, increasing the ratio of angiogenic to antiangiogenic 
factors and promoting abnormal neovascularization in the 
retina [5]. During ischemia, increasing levels of the heterodi-
meric hypoxia-inducible factor-1 (HIF-1) are detected [11,12]. 
Both HIF-1 subunits are constitutively expressed, but in 
normoxia conditions, the HIF-1α subunit is rapidly degraded 
by an oxygen-dependent mechanism [13]. However, in a 
hypoxic environment both HIF-1 subunits form dimers and 
translocate to the nucleus, where they can induce the tran-
scription of a wide range of genes [14-16], including VEGF 
(Gene ID: 7422; OMIM: 192240) [17], EPO (Gene ID: 2056; 
OMIM: 133170) [18], and the glucose transporter 1 (GLUT1; 
Gene ID: 6513; OMIM: 138140) [19].
GLUT1 is one of the 12 GLUT isoforms described [20], 
composed of a glycoprotein with 12 transmembrane domains 
Molecular Vision 2016; 22:761-770 <http://www.molvis.org/molvis/v22/761>
Received 25 January 2016 | Accepted 12 July 2016 | Published 14 July 2016
© 2016 Molecular Vision
761
GLUT1 activity contributes to the impairment of PEDF secretion 
by the RPE
Sofia M. Calado,1,2 Liliana S. Alves,2,3 Sónia Simão,2,4 Gabriela A. Silva2
1PhD Program in Biomedical Sciences, Department of Biomedical Sciences and Medicine, University of Algarve, Campus 
Gambelas, Faro, Portugal; 2CEDOC, NOVA Medical School | Faculdade de Ciências Médicas, Universidade Nova de Lisboa, 
Campo Mártires da Pátria, Lisboa, Portugal; 3ProRegeM PhD Program, NOVA Medical School/Faculdade de Ciências 
Médicas, Universidade Nova de Lisboa, Campo Mártires da Pátria, Lisboa, Portugal; 4Centre for Biomedical Research (CBMR), 
University of Algarve, Campus Gambelas, Faro, Portugal
Purpose: In this study, we aimed to understand whether glucose transporter 1 (GLUT1) activity affects the secretion 
capacity of antiangiogenic factor pigment epithelium-derived factor (PEDF) by the RPE cells, thus explaining the reduc-
tion in PEDF levels observed in patients with diabetic retinopathy (DR).
Methods: Analysis of GLUT1 expression, localization, and function was performed in vitro in RPE cells (D407) cultured 
with different glucose concentrations, corresponding to non-diabetic (5 mM of glucose) and diabetic (25 mM of glucose) 
conditions, further subjected to normoxia or hypoxia. The expression of PEDF was also evaluated in the secretome of 
the cells cultured in these conditions. Analysis of GLUT1 and PEDF expression was also performed in vivo in the RPE 
of Ins2Akita diabetic mice and age-matched wild-type (WT) controls.
Results: We observed an increase in GLUT1 under hypoxia in a glucose-dependent manner, which we found to be 
directly associated with the translocation and stabilization of GLUT1 in the cell membrane. This stabilization led to 
an increase in glucose uptake by RPE cells. This increase was followed by a decrease in PEDF expression in RPE cells 
cultured in conditions that simulated DR. Compared with non-diabetic WT mice, the RPE of Ins2Akita mice showed 
increased GLUT1 overexpression with a concomitant decrease in PEDF expression.
Conclusions: Collectively, our data show that expression of GLUT1 is stimulated by hyperglycemia and low oxygen 
supply, and this overexpression was associated with increased activity of GLUT1 in the cell membrane that contributes 
to the impairment of the RPE secretory function of PEDF.
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and a single N-glycosylation site. GLUT1 transports glucose 
bidirectionally across the cell membrane based on a concen-
tration gradient [20,21]. In the retina, as in the brain, glucose 
is the only fuel source for cells, and in both tissues, glucose 
is transported to cells exclusively through the GLUT1 trans-
porter [20,22].
In this study, we aimed to establish a correlation between 
RPE, GLUT1, and their role in diabetic retinopathy. Our 
hypothesis is that under diabetic conditions, where there is 
an increase in glucose and local hypoxia, the expression of 
GLUT1 in RPE cells is increased, and that can affect the 
secretory function of the RPE, namely, the production of 
PEDF. This change in PEDF secretion can lead to an imbal-
ance between VEGF and PEDF, contributing to diabetic 
retinopathy. To test our hypothesis, we studied the effect of 
hyperglycemia and hypoxia on the cellular localization and 
expression of GLUT1 and PEDF expression on RPE cells and 
further confirmed our findings in a mouse model of diabetic 
retinopathy.
METHODS
Cell lines: D407, a human RPE cell line [23] used in the in 
vitro experiments, was kindly provided by Dr. Jean Bennett 
of the University of Pennsylvania. Cells were kept in culture 
in a humid chamber with 5% CO2 at 37 °C and were grown 
in Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma 
Aldrich, St. Louis, MO) supplemented with 1% penicillin/
streptomycin (Sigma-Aldrich), 1% glutamine (Sigma-
Aldrich), and 5% fetal bovine serum (Sigma-Aldrich). 
Culture medium was changed every 2 days. For the experi-
ments on the glucose effect, cells were cultured in 22.1 cm2 
plates (TPP, Trasadingen, Switzerland) for 3 days either in 
DMEM containing 5 mM D-glucose (to simulate normogly-
cemia) or in DMEM with 25 mM of D-glucose (to simulate 
hyperglycemia). Cells were also grown in DMEM containing 
5 mM of D-glucose in which mannitol was added up to a final 
concentration of 25 mM. Mannitol was chosen as an osmotic 
control because it is a carbohydrate with no biologic activity 
and cannot be used by the cells as a source of energy [7,24]. 
Hypoxia was induced by the addition of desferrioxamine 
[25,26] (DFO, Sigma-Aldrich) to the culture media at a final 
concentration of 100 µM. DFO is an iron chelating agent 
often used as a hypoxia-mimetic agent to stabilize HIF- 1α 
[25]. Under normoxic conditions and in the presence of iron, 
HIF-1α is hydroxylated and subsequently degraded by the 
proteasome. In the presence of DFO, the iron required for 
the enzymatic activity of prolyl hydroxylases is removed by 
its chelating capacity, allowing HIF-1α to be stabilized and 
dimerize with its β-subunit, originating a functional complex 
that is translocated to the nucleus [25]. After 16 h of incu-
bation with DFO, cells were collected for western blot and 
immunocytochemistry for GLUT1.
Detection of GLUT1 expression by western blot: Whole cell 
proteins were extracted in cold RIPA buffer (50 mM Tris-HCl 
pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 
and 1 mM EDTA) supplemented with a protease inhibitor 
cocktail (Roche, Basel, Switzerland). For isolation of the 
membrane/soluble fractions, cells were extracted in cold 
homogenization buffer (20 mM HEPES pH 7.4; 1 mM EDTA; 
250 mM sucrose) containing a protease inhibitor cocktail. 
The lysate was cleared by centrifugation at 4 °C for 10 min 
at 1,137 ×g. The supernatant was centrifuged at 100,000 ×g 
for 1 h at 4 °C, and the pellet corresponding to the membrane 
fraction was resuspended in buffer (10 mM HEPES pH 7.4; 
250 mM sucrose) supplemented with a protease inhibitor 
cocktail. Protein content was measured with the Bradford 
assay, and the samples were stored at −80 °C. Thirty micro-
grams of each extract were separated in a denaturing 12% 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
(SDS–PAGE) gel. The proteins were transferred to a poly-
vinylidene difluoride (PVDF) membrane (Amersham, Little 
Chalfont, UK) and blocked using Superblock Blocking buffer 
(Thermo Scientific) containing 0.1% of Tween-20 (Sigma-
Aldrich) for 1 h at room temperature. GLUT1 antibody 
(ab32551; Abcam, Cambridge, UK) was incubated overnight 
at 4 °C (1:2,000 dilution) and β-actin (A5441, Sigma-Aldrich) 
was incubated for 1 h at room temperature (1:10,000 dilu-
tion). The membrane was probed with a horseradish peroxi-
dase (HRP)-conjugated secondary antibody for 1 h at room 
temperature, and the immunoreactive bands were detected 
with chemiluminescence, using an ECL Plus kit (Amersham).
Cellular localization of GLUT1 with immunocytochemistry: 
The cells were fixed in ice-cold methanol for 10 min, washed 
twice in PBS (1X; 137 mM NaCl, 10 mM NaPO4, 2.7 mM 
KCl, 2 mM KPO4, pH 7.4), and blocked in 1% goat serum/
PBS at room temperature for 1 h. Incubation with the GLUT1 
antibody (1:250) was performed for 1 h at room temperature, 
followed by a wash step and incubation with the secondary 
antibody (Alexa Fluor® 594; 1:500; Life Technologies, 
Walthman, MA) at room temperature for 1 h. Coverslips were 
mounted on glass slides with Fluoromount G (SouthernBio-
tech, Birmingham, AL) containing 4',6-diamidino-2-phenyl-
indole (DAPI). Images were obtained using an AxioVision 
microscope with a 63× objective, using the appropriate filter 
sets (Axio Observer Z2, Zeiss, Oberkochen, Germany).
Glucose consumption assay: For determining glucose 
consumption by glucose depletion from the culture medium, 
D407 cells were seeded at a density of 7.0 × 105 cells/well in 
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six-well flat-bottom tissue culture plates and maintained for 
72 h in culture medium containing 25 mM of D-glucose. A 
sample of culture medium was collected from each well, and 
the glucose concentration was determined spectrophotometri-
cally using the Glucose (GO) Assay Kit (Sigma-Aldrich), 
following the manufacturer’s instructions. Culture medium 
with 25 mM of D-glucose was used as control.
PEDF detection in the culture medium of the RPE cells: The 
cells were grown as previously described, and 16 h before the 
supernatant was collected, the cells were washed with PBS 
and 1 ml of culture medium without serum was added. PEDF 
levels were detected with western blot in the culture medium. 
Briefly, the supernatant was collected, and four volumes of 
ice-cold acetone were added. After an incubation period of 
30 min at −20 °C, the supernatant was centrifuged for 10 min 
at 13,000 ×g and decanted. The pellet containing the precipi-
tated proteins was resuspended in 1X Sample Buffer. Protein 
content was measured with the Bradford assay, and 30 μg of 
each extract were separated in a denaturing 12% SDS–PAGE 
gel and transferred to a nitrocellulose membrane (Bio-Rad, 
Berkeley, CA). Equal amounts of protein were loaded in the 
gel, determined by Ponceau S staining of the membranes 
before blocking. Western blot was performed as described 
previously, using a PEDF antibody (07–280, Merck Millipore, 
Billerica, MA; 1:1,000).
Animals: For the in vivo experiments, male C57BL/6 (wild-
type) and C57Bl/6 Ins2Akita (diabetic) mice (The Jackson 
Laboratory, Farmington, CT) 2, 4, 7, and 10 months after 
the onset of hyperglycemia (2 months after birth) were used. 
The animals were housed under controlled temperatures and 
a 12 h:12 h light-dark cycle with food and water ad libitum. 
Diabetic phenotype was confirmed 2 months after birth by 
measuring blood glucose levels in a drop of blood from a tail 
puncture (Freestyle Precision, Abbot, Lake Bluff, IL), with 
animals used in this study exhibiting blood glucose ≥500 mg/
dl. All experimental procedures were performed according 
to the Portuguese and European Laboratory Animal Science 
Association (FELASA) Guide for the Care and Use of Labora-
tory Animals, the European Union Council Directive 2010/63/
EU for the Use of Animals in Research, and the guidelines of 
the Association for Research in Vision and Ophthalmology 
(ARVO) for the Use of Animals in Ophthalmic and Vision 
Research. Animals were humanely euthanized by cervical 
dislocation and the eyes enucleated. The RPE was isolated by 
dissection of the eyeball and homogenized in ice-cold RIPA 
buffer.
Statistical analysis: All experiments were performed in 
triplicate, and the results expressed as mean ± standard error 
of the mean (SEM). Statistical analysis was performed by 
using a two-way ANOVA, followed by a Tukey’s or Sidak’s 
multiple comparisons test or an unpaired t-test, depending 
on the experiment. The data were analyzed using GraphPad 
Prism software. A p value of less than 0.05 was considered 
statistically significant.
RESULTS
Hypoxia induces overexpression of GLUT1 in RPE cells: 
To evaluate the effects of glucose and ischemia in GLUT1 
expression within the oBRB, we used an in vitro setup with 
human RPE cells. D407 cells were cultured either with 5 mM 
of D-glucose (corresponding to normoglycemia) or 25 mM 
of D-glucose (corresponding to hyperglycemia) and further 
subjected to hypoxia by the addition of DFO, a chelating 
agent that induces hypoxia by inhibiting HIF-1α degradation 
at the proteasome [25,26]. We confirmed that DFO does not 
induce cell death at the final concentration of 100 µM (data 
not shown).
Figure 1 shows no differences at the protein level in cells 
in normoglycemic conditions under normoxia (N), when 
compared with hypoxia (H). However, there is a significant 
increase in GLUT1 protein in the cells cultured with 25 mM 
of D-glucose in hypoxia compared with the cells cultured in 
normoxia, showing a direct effect of the glucose concentra-
tion on GLUT1 expression.
GLUT1 translocation to the cell membrane of RPE cells 
increases in response to hypoxia: To determine whether 
the increase in GLUT1 expression observed in Figure 1 
corresponded to an increase in the transport of glucose, 
we first determined the cellular localization of GLUT1 in 
human RPE cells with immunocytochemistry. The results 
showed a significant increase in the accumulation of GLUT1 
in the membrane of the cells under hypoxia compared with 
the cells under normoxia (Figure 2). Again, we observed 
GLUT1 staining to be stronger in the cells in hypoxia and 
hyperglycemia compared with the cells in hypoxia and 
normoglycemia.
We confirmed these results with western blot analysis 
of the membrane and soluble fractions of RPE cells cultured 
in high glucose either in normoxia or hypoxia (Figure 3). 
In Figure 3, it is clear the marked increase of the GLUT1 
transporter in the membrane of cells in hypoxia compared 
to normoxia, which correlates with the results shown in 
Figure 2. We could not observe an increase in GLUT1 in the 
soluble fraction of cells in hypoxia, which was expected since 
GLUT1 is a membrane transporter.
Glucose consumption is affected by hypoxia: Based on 
the finding that GLUT1 expression is increased in the cell 
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Figure 1. Effect of glucose and hypoxia on GLUT1 expression. Western blot analysis of GLUT1 in D407 RPE cells cultured under normoxia 
(N) and hypoxia (H) conditions and different concentrations of glucose in the culture medium: 5 mM of D-glucose (corresponding to 
normoglycemia), 25 mM of D-glucose (corresponding to hyperglycemia), and 25 mM of mannitol (osmolarity control). Quantitative data 
were obtained by normalization with β-actin bands. n = 4. *p<0.05 represents a significant difference in GLUT1 levels in cells cultured 
under hypoxia with high glucose concentration medium, determined with Tukey’s multiple comparisons test.
Figure 2. Immunocytochemistry for GLUT1 in RPE cells. D407 cells were cultured with different concentrations of glucose and subjected to 
hypoxia and normoxia. Staining for GLUT1 (red) shows higher intensity in the cell membrane of cells subjected to hypoxia. 4',6-diamidino-
2-phenylindole (DAPI; blue) represents the nuclei. Magnification = 630X, scale bar = 20 µM.
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membrane of the RPE cells subjected to hypoxia, it was 
necessary to determine if this translates into increased 
glucose uptake by RPE cells. GLUT1 activity was measured 
by glucose consumption through glucose depletion in the 
culture medium. We found a significant increase in glucose 
consumption induced by hypoxia (Figure 4), with the cells 
consuming 60% of the glucose present in the culture medium 
compared to the 40% consumption in normoxia. This shows a 
marked effect of hypoxia on glucose consumption in diabetic 
retinopathy conditions.
Secretory function of RPE cells is impaired by high glucose 
and hypoxia: One of the main functions of RPE cells is 
the secretion of multiple trophic factors essential for the 
maintenance and integrity of the neuroretina and chorio-
capillaries [2]. One of these factors is PEDF, a neurotrophic 
and antiangiogenic factor responsible for protecting neurons 
from ischemia-induced apoptosis [27] and inhibiting endo-
thelial cell proliferation caused by VEGF [28]. We evaluated 
the expression of PEDF in RPE cells cultured as described 
previously and found a significant decrease in PEDF levels 
for conditions where cells were cultured in hyperglycemia 
(25 mM glucose) and hypoxia (H; Figure 5). This result 
shows that in diabetic conditions there is a decrease in the 
secretion of PEDF, which contributes to the disruption of the 
balance between the antiangiogenic and angiogenic factors, 
as observed in human diabetic retinas [29,30].
Figure 3. GLUT1 expression is stabilized in the cell membrane in response to hypoxia. GLUT1 protein levels in the soluble and membrane 
fraction of D407 cells cultured with 25 mM of D-glucose and subjected to normoxia and hypoxia, show a marked increase in GLUT1 
expression in the membrane of cells cultured in hypoxic conditions. n = 3. *p<0.05 symbolizes a significant increase in GLUT1 expression 
in the membrane fraction of the cells cultured under hypoxia with high glucose concentration medium, determined with Sidak’s multiple 
comparisons test.
Figure 4. Glucose consumption by 
RPE cells. Glucose depletion from 
the culture medium was increased 
for cells cultured under hypoxia, 
compared with cells in normoxia. 
The results are expressed as 
percentage of the control (culture 
medium). n = 6. *p<0.05 denotes 
a significant difference in glucose 
consumption by cells in hypoxia 
compared with cells in normoxia, 
determined with the two-tailed t 
test.
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GLUT1 and PEDF expression is altered in the RPE of 
diabetic mice: To confirm the validity of our in vitro find-
ings, we analyzed the expression of GLUT1 and PEDF in the 
RPE of wild-type and Ins2Akita diabetic mice (Figure 6). For 
all time points (2, 4, 7, and 10 months after the onset of hyper-
glycemia), GLUT1 expression was significantly increased 
in the retina of diabetic mice compared with age-matched 
wild-type animals. Additionally, we found a marked decrease 
in PEDF levels in the RPE of the diabetic mice, especially 
at later ages. These in vivo results corroborate our in vitro 
results in which we found an increase in GLUT1 (Figure 1) 
and a decrease in PEDF secretion by RPE cells cultured in 
conditions simulating DR (Figure 5).
DISCUSSION
DR is one of the most frequent complications of diabetes 
mellitus, affecting about 90% of patients with type 1 diabetes 
[31]. It is known that hyperglycemia and ischemia are key 
factors for the progression of the disease [5]; however, the 
mechanism by which hyperglycemia contributes to the devel-
opment of the disease remains unclear [1]. DR is traditionally 
characterized as a blood–retinal barrier disorder, in which 
the leakage of blood content, due to pathological neovascu-
larization, is the main feature of the disease [1]. Although 
the iBRB breakdown has been extensively investigated, the 
effects of diabetes on the RPE cells composing the oBRB are 
still not well-known [2]. The RPE monolayer is extremely 
important to maintain the homeostasis of the neural retina 
[2] suggesting that its impairment can compromise the retinal 
function.
The retina is one of the most metabolically active tissues 
in the human body and glucose is the retina’s only source of 
energy [32]. In the retina, glucose transport is exclusively 
mediated by GLUT1 [9]. To better characterize GLUT1 
expression in conditions of DR, we devised a series of in 
vitro experiments using D407 cells, a spontaneously trans-
formed human RPE cell line derived from a primary culture 
of human RPE cells [23]. These cells are extensively used 
as in vitro models and are suitable for studying molecular 
mechanisms of the RPE [33,34]. RPE cells were exposed to 
different concentrations of glucose to mimic normoglycemia 
(5 mM of D-glucose) and hyperglycemia (25 mM D-glucose). 
In addition, cells were also exposed to hypoxia to simulate 
retinal ischemia observed in patients with DR [5]. It was 
previously shown that hypoxia induces overexpression of 
GLUT1 in mouse fibroblasts in response to metabolic adap-
tation [19], but there was no evidence regarding changes in 
GLUT1 expression due to hypoxia in RPE cells. Our western 
blot analysis showed no differences in GLUT1 protein 
expression in the cells cultured with normoglycemic medium 
Figure 5. Effects of glucose and 
hypoxia in PEDF secretion by 
RPE cells. Western blot analysis 
of pigment epithelium-derived 
factor (PEDF) secretion in D407 
cells cultured under normoxia 
(N) and hypoxia (H) conditions 
and different concentrations of 
glucose in the culture medium: 5 
mM of D-glucose (corresponding 
to normoglycemia), 25 mM of 
D-glucose (cor responding to 
hyperglycemia), and mannitol 
(osmolarity control). n = 4. *p<0.05 
represents a significant decrease in 
PEDF secretion by the RPE cells 
cultured under hypoxia with high 
glucose concentration medium, 
determined with Tukey’s multiple 
comparisons test.
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(Figure 1). In contrast, it is possible to observe that hypoxia 
induces a significant increase in GLUT1 protein levels in the 
cells cultured with 25 mM of D-glucose compared with the 
control cells cultured in normoglycemic (5 mM of D-glucose) 
medium. This suggests that the diabetic environment induced 
by high glucose and hypoxia most likely contributes to the 
overexpression of GLUT1. Analysis of protein expression 
with immunocytochemistry shows an increase in GLUT1 
staining in the cell membrane of the RPE cells in response 
to hypoxia (Figure 2). Similarly to the previous western blot 
results shown in Figure 1, the staining is stronger in cells 
cultured with 25 mM of D-glucose, which further supports 
the contribution of high glucose levels for the expression of 
GLUT1. To confirm this finding, we isolated the membrane 
and soluble fractions of D407 cells cultured with 25 mM of 
D-glucose. We found a marked increase in GLUT1 expres-
sion in the membrane fraction of cells in hypoxic condi-
tions compared with cells cultured with the same glucose 
concentration in normoxia (Figure 3). Interestingly, the 
soluble concentration of GLUT1 is similar in both conditions, 
suggesting that the increase in GLUT1 expression observed 
in the whole cell lysates (Figure 1) is due to an increase in 
GLUT1 expression in the cell membrane (Figure 3). These 
results are in accordance with what was previously shown 
for GLUT4 in cardiomyocytes, where hypoxia induces the 
translocation of this protein to the cell membrane [35]. It is 
known that in response to low levels of oxygen cells shift 
their glucose metabolism to anaerobic respiration, which is 
much less efficient [36]. The translocation of GLUT1 to the 
cell membrane can be a response to achieve a more effec-
tive glucose uptake in low oxygen conditions. To test this, 
we performed a glucose consumption assay in which the 
glucose remaining in the culture medium was measured in 
cells cultured under normoxia and hypoxia. Our results show 
that cells under hypoxia display higher glucose consump-
tion compared with cells cultured under normoxia (Figure 
4), showing an increase in glucose uptake by GLUT1 under 
hypoxia.
As previously stated, one of the main functions of RPE 
cells is their secretory capacity, responsible for producing and 
secreting a wide range of factors that support photoreceptors 
and guaranteeing optimal circulation and supply of nutrients 
[2,37]. One of those factors is PEDF, a neurotrophic and anti-
angiogenic factor secreted by RPE cells that acts by inhibiting 
retinal endothelial cell growth and migration [38].
Several studies have shown an imbalance between VEGF 
and PEDF levels in the vitreous of diabetic patients, showing 
Figure 6. Secretory function of 
RPE is impaired in Ins2Akita mice. 
Pigment epithelium-derived factor 
(PEDF) and GLUT1 protein expres-
sion was assessed with western 
blot of RPE tissue from diabetic 
mice with 2, 4, 7, and 10 months of 
hyperglycemia (HG) and compared 
with age-matched wild-type 
(WT) controls. Quantitative data 
were obtained by normalization 
of β-actin bands and represents 
GLUT1 and PEDF expression in 
Ins2Akita related to WT (control). n = 
6. ns represents non-significant data 
determined with Sidak’s multiple 
comparisons test, p<0.05.
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that the secretory function of RPE might be impaired 
[29,30,39]. A significant decrease in PEDF secreted by 
cells cultured with high glucose and subjected to hypoxia is 
observed in Figure 5, showing that the increase in glucose 
uptake by GLUT1 has a negative impact in the PEDF expres-
sion. Additionally, as we have previously shown, there is a 
concomitant increase in the expression of angiogenic VEGF 
and a decrease in the antiangiogenic isoform VEGF165b [40,41].
Our in vitro findings were also confirmed in vivo in 
the RPE of the diabetic Ins2Akita mice, compared with non-
diabetic WT mice. The Ins2Akita mouse is a non-obese model 
of type 1 diabetes that has been widely used as a model of 
DR [42-44]. This mouse model is considered a more reli-
able model to study diabetes mellitus complications as this 
model develops the disease spontaneously [40] in contrast 
with the Streptozotocin (STZ) models. In Ins2Akita animals, 
hyperglycemia starts approximately at 4 weeks after birth, 
with retinal complications visible approximately 3 months 
after the onset of hyperglycemia, including vascular leakage, 
loss of pericytes, thickening of the inner retinal layers [42], 
and increase in angiogenic markers such as VEGF [44]. In the 
present study, we found a marked increase in GLUT1 expres-
sion in the RPE of diabetic mice, 4, 7, and 10 months after the 
onset of hyperglycemia, when compared with non-diabetic 
WT animals (Figure 6). This is consistent with the findings 
of Badr and coworkers in SZT-induced diabetic mice where 
the fraction of glucose entering the retina is higher across the 
RPE than across the iBRB [6].
We found a significant decrease in PEDF expression in 
the RPE of the diabetic mice, showing a significant impair-
ment of the neurotrophic secretory function of RPE imme-
diately after the onset of the disease. These results together 
with our in vitro results and the work of others [42] confirm 
the imbalance between pro- and antiangiogenic factors in the 
retina in this diabetic mouse model. Although they observed 
no significant decrease in PEDF levels in the neuroretina 
(which excludes the RPE) of diabetic mice before 7 months 
of hyperglycemia (corresponding to 9 months of age), we 
found a significant decrease in PEDF expression by RPE 
cells 2 months after the onset of hyperglycemia [44]. This 
result points to the possibility that in DR the oBRB is affected 
before the iBRB.
Further studies will focus on determining whether this 
increase in GLUT1 expression and activity can explain the 
increase in levels of reactive oxygen species (ROS) [43] and 
advanced glycation end products (AGEs) [44]. Additionally, 
our laboratory is studying whether the well-studied upregula-
tion of VEGF by ROS, AGEs [45], and hypoxia itself can 
contribute to the decrease in PEDF secretion by RPE cells, 
thus promoting the imbalance between PEDF and VEGF that 
is visible in patients with DR.
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